IL154311A0 - Modulating multiple lineage kinase proteins - Google Patents
Modulating multiple lineage kinase proteinsInfo
- Publication number
- IL154311A0 IL154311A0 IL15431101A IL15431101A IL154311A0 IL 154311 A0 IL154311 A0 IL 154311A0 IL 15431101 A IL15431101 A IL 15431101A IL 15431101 A IL15431101 A IL 15431101A IL 154311 A0 IL154311 A0 IL 154311A0
- Authority
- IL
- Israel
- Prior art keywords
- kinase proteins
- lineage kinase
- multiple lineage
- modulating multiple
- modulating
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Wood Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63705400A | 2000-08-11 | 2000-08-11 | |
PCT/US2001/024822 WO2002014536A2 (en) | 2000-08-11 | 2001-08-08 | Odulating multiple lineage kinase proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
IL154311A0 true IL154311A0 (en) | 2003-09-17 |
Family
ID=24554347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15431101A IL154311A0 (en) | 2000-08-11 | 2001-08-08 | Modulating multiple lineage kinase proteins |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1309721A2 (zh) |
JP (1) | JP2005503102A (zh) |
CN (1) | CN1458979A (zh) |
AU (2) | AU2001283179B2 (zh) |
BG (1) | BG107623A (zh) |
BR (1) | BR0113266A (zh) |
CA (1) | CA2419985A1 (zh) |
CZ (1) | CZ2003680A3 (zh) |
HR (1) | HRP20030162A2 (zh) |
HU (1) | HUP0501110A3 (zh) |
IL (1) | IL154311A0 (zh) |
IS (1) | IS6711A (zh) |
MX (1) | MXPA03001218A (zh) |
NO (1) | NO20030658L (zh) |
NZ (1) | NZ524034A (zh) |
PL (1) | PL366248A1 (zh) |
SK (1) | SK2692003A3 (zh) |
WO (1) | WO2002014536A2 (zh) |
ZA (1) | ZA200301109B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
AU2004257748B2 (en) * | 2003-07-14 | 2008-10-30 | Decode Genetics Ehf. | Method of diagnosis and treatment for asthma based on haplotype association |
US20060058250A1 (en) * | 2004-09-10 | 2006-03-16 | Cephalon, Inc. | Methods of treating proliferative skin diseases using carbazole derivatives |
WO2014172616A2 (en) * | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
NZ754020A (en) * | 2016-11-25 | 2022-11-25 | Genuv Inc | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756494A (en) * | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
ATE293254T1 (de) * | 1998-08-26 | 2005-04-15 | Cephalon Inc | Modulierung von mlk- (multiple lineage kinase) proteinen |
US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
-
2001
- 2001-08-08 IL IL15431101A patent/IL154311A0/xx unknown
- 2001-08-08 CN CN01814001A patent/CN1458979A/zh active Pending
- 2001-08-08 CA CA002419985A patent/CA2419985A1/en not_active Abandoned
- 2001-08-08 HU HU0501110A patent/HUP0501110A3/hu unknown
- 2001-08-08 AU AU2001283179A patent/AU2001283179B2/en not_active Ceased
- 2001-08-08 WO PCT/US2001/024822 patent/WO2002014536A2/en active Application Filing
- 2001-08-08 AU AU8317901A patent/AU8317901A/xx active Pending
- 2001-08-08 JP JP2002519661A patent/JP2005503102A/ja active Pending
- 2001-08-08 MX MXPA03001218A patent/MXPA03001218A/es not_active Application Discontinuation
- 2001-08-08 CZ CZ2003680A patent/CZ2003680A3/cs unknown
- 2001-08-08 BR BR0113266-0A patent/BR0113266A/pt not_active IP Right Cessation
- 2001-08-08 PL PL01366248A patent/PL366248A1/xx not_active Application Discontinuation
- 2001-08-08 NZ NZ524034A patent/NZ524034A/en unknown
- 2001-08-08 EP EP01961958A patent/EP1309721A2/en not_active Withdrawn
- 2001-08-08 SK SK269-2003A patent/SK2692003A3/sk not_active Application Discontinuation
-
2003
- 2003-02-10 ZA ZA200301109A patent/ZA200301109B/en unknown
- 2003-02-10 IS IS6711A patent/IS6711A/is unknown
- 2003-02-10 NO NO20030658A patent/NO20030658L/no not_active Application Discontinuation
- 2003-03-06 HR HR20030162A patent/HRP20030162A2/hr not_active Application Discontinuation
- 2003-03-10 BG BG107623A patent/BG107623A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005503102A (ja) | 2005-02-03 |
PL366248A1 (en) | 2005-01-24 |
WO2002014536A9 (en) | 2003-12-18 |
BG107623A (bg) | 2003-11-28 |
HUP0501110A3 (en) | 2006-06-28 |
HUP0501110A2 (en) | 2006-03-28 |
SK2692003A3 (en) | 2003-08-05 |
IS6711A (is) | 2003-02-10 |
WO2002014536A2 (en) | 2002-02-21 |
CA2419985A1 (en) | 2002-02-21 |
CZ2003680A3 (cs) | 2003-11-12 |
NO20030658D0 (no) | 2003-02-10 |
ZA200301109B (en) | 2004-07-20 |
AU2001283179B2 (en) | 2006-07-13 |
NZ524034A (en) | 2006-11-30 |
NO20030658L (no) | 2003-04-09 |
CN1458979A (zh) | 2003-11-26 |
AU8317901A (en) | 2002-02-25 |
MXPA03001218A (es) | 2003-05-27 |
HRP20030162A2 (en) | 2005-12-31 |
WO2002014536A3 (en) | 2003-01-30 |
EP1309721A2 (en) | 2003-05-14 |
BR0113266A (pt) | 2005-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0001704D0 (en) | Protein | |
HUP0103079A3 (en) | Modulating multiple lineage kinase proteins | |
GB0011185D0 (en) | Protein | |
IL154311A0 (en) | Modulating multiple lineage kinase proteins | |
AU2001287914A1 (en) | Protein kinase regulation | |
GB0027905D0 (en) | New protein | |
GB0024446D0 (en) | Protein | |
GB9803399D0 (en) | Protein kinase c | |
GB0006143D0 (en) | Multiple sequence alignment | |
GB0012216D0 (en) | Glycosyltransferase protein | |
GB0006539D0 (en) | Therapies | |
AU2001284272A1 (en) | Kinase d interacting protein | |
GB0025677D0 (en) | New protein | |
GB0009181D0 (en) | Protein | |
IL150774A0 (en) | Apoptin-associating protein | |
EP1323734A4 (en) | BINDING PROTEIN TO IRAP | |
GB0013807D0 (en) | Tyrosine kinase modulators | |
AU2002210705A1 (en) | Protein kinase | |
AU2002222122A1 (en) | Protein kinase | |
GB0020345D0 (en) | Protein | |
GB0008549D0 (en) | Protein | |
GB0023243D0 (en) | Protein kinase regulation | |
GB0019873D0 (en) | Stable protein selection | |
GB0027308D0 (en) | Drug-activated proteins | |
GB0010596D0 (en) | New protein |